Clinical Trials Browser

Interventional × J591 monoclonal antibody × Clear all

Prostatic Neoplasms

NCT00967577 2022-02-02

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioma, Head and Neck Neoplasms, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02693860 2020-10-05

Neoadjuvant J591 Treatment for Prostate Cancer

Phase 1 Completed

8 enrolled

Genitourinary

Prostatic Neoplasms

NCT00040586 2007-01-22

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Phase 2 Completed

Genitourinary

Prostatic Neoplasms

Clinical Trials

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Neoadjuvant J591 Treatment for Prostate Cancer

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2